In vitro and computational analysis reveals stereoselective binding of S-(+)-penthiopyrad to serum albumin, highlighting greater toxicological risk from the S-enantiomer.
Chiral pesticides, such as penthiopyrad, consist of enantiomers with differing biological activities and toxicological profiles, potentially leading to environmental risks. This study investigates the stereoselective binding of the R-(-)- and S-(+)-enantiomers of penthiopyrad to bovine and human serum albumin (BSA/HSA) using a combination of spectroscopic techniques, density functional theory (DFT) calculations, and molecular docking. The results indicate that S-(+)-penthiopyrad exhibits a significantly stronger quenching effect on the intrinsic fluorescence of both HSA and BSA than R-(-)-penthiopyrad, suggesting a higher binding affinity, which is consistent with DFT predictions. Specifically, the binding constants ( ΔG ) of S-(+)-penthiopyrad with BSA and HSA were -31.80 kJ/mol and -35.68 kJ/mol, respectively, compared to -30.42 kJ/mol and -33.82 kJ/mol for R-(-)-penthiopyrad. Circular dichroism (CD) spectroscopy and FTIR analysis show that both enantiomers induce conformational changes in albumin secondary structures, reducing α-helical content by 3.6% for S-(+)-penthiopyrad and 2.1% for R-(-)-penthiopyrad in BSA, and by 2.7% and 0.2%, respectively, in HSA. Molecular docking identifies site II (subdomain IIIA) as the primary binding region, with hydrogen bonding and hydrophobic interactions stabilizing the S-(+)-penthiopyrad complex more effectively. These findings underscore the higher environmental risk of S-(+)-penthiopyrad compared to R-(-)-penthiopyrad, advancing the molecular-level understanding of stereoselective behavior in chiral fungicides and guiding safer agrochemical development. • Enantioselective effect of S-(+)-penthiopyrad and R-(-)-penthiopyrad has been studied at molecular level. • Binding of chiral penthiopyrad to BSA/HSA alters the microenvironment of BSA/HSA . • The potential toxicity of the S-(+)-penthiopyrad is higher than the R-(-)-penthiopyrad.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: